Your Longevity Doctor Search Is Over: Introducing longevitydocs.network
Issue 72: The front page of longevity medicine - curated by doctors, for doctors.
Hey Doc,
Last week’s post on The Biomarkers Gold Rush sparked an unexpected wave of conversation across our entire field.
The takeaway was universal: No matter how fast biomarkers scale, physicians will always be the ones who turn numbers into clinical outcomes.
And that brings us to today’s announcement.
Healthy Sunday!
PS: cover image generated by Google AI Studio
Dr. David Luu
Founder, longevitydocs.™, the world’s largest physician network in longevity medicine, serving 600+ vetted physicians across 50+ countries. We unite physicians, industry, and institutions to build the trusted global infrastructure that makes longevity medicine the new standard of care.
Longevity medicine is the personalized, evidence-based practice of modifying the root mechanisms of aging (biological, cognitive, and psychosocial) before they become disease, extending healthspan, not just lifespan. Using advanced diagnostics, precision interventions, and AI-enabled monitoring, it translates measurement into action across every medical discipline. Success is measured in functional capacity, vitality, and disease-free years.
Each week, I try to explore one idea that could advance longevity medicine and hopefully support physicians in bringing it to life.
Your Longevity Doctor Search Is Over
The longevity space is accelerating fast. Biomarkers, wearables, and AI are everywhere. But every company I speak with hits the same wall:
You can find doctors. You can’t find doctors trained in longevity medicine.
You hire brilliant clinicians—but they were trained to treat disease, not optimize healthspan. They can manage heart failure, diabetes, cancer. But ask them to interpret biological age reports, design healthspan protocols, or validate longevity products, and the expertise gap shows up immediately.
This isn’t about talent. It’s about expertise.
Longevity medicine is proactive, preventive, data-driven, and interdisciplinary. Most physicians were never taught this. And that’s exactly why we built the next evolution.
Introducing longevitydocs.network
The enterprise network connecting world-class longevity physicians with companies building the future of healthspan.
Over the last two years, Longevity Docs evolved from a community → to conferences → to certification → to research network.
Today, we’re launching the clinical infrastructure our industry has been missing: a curated group of 50 U.S.-based longevity physicians who can lead your trials, validate your products, build your prevention programs, and establish your medical credibility.
L’Oréal Group and Mount Sinai already trust this network. Now it’s available to you.
Not a consumer directory. Not a marketplace. Not a referral service.
This is the physician layer behind the next decade of longevity innovation.
5 ways to partner
Executive Leadership & Medical Oversight
CMOs and medical directors who build credible, compliant longevity-focused care and strategy.Clinical Research & Trial Leadership
GCP-certified PIs who understand healthspan endpoints and longevity trial design - with access to patient populations for trial recruitment.Strategic Medical Advisory
Advisors who blend longevity science with real operational and business insight.Product Validation & Protocol Development
Physicians who can validate biomarkers, refine claims, and ensure safety.Physician-Led Education & Content
Certification-level training and medical content that builds trust and authority.
Why now
Longevity medicine is becoming a $7T global economy. The long-term moves start now. Health systems, pharma, biotech, and consumer leaders are looking for physician-led research, care, and education.
Medical credibility is no longer optional. It’s the moat.
This is longevitydocs.network.
Your longevity doctor search is over.
→ Founding Partners Only:
We’re accepting just few companies per category (biotech, pharma, health systems, consumer brands, longevity clinics) for white-glove partnership during our beta launch. Early partners get priority physician access, dedicated support, and category positioning. Apply now - once your category fills, the opportunity closes.
Every week, the Longevity Docs WhatsApp group feels like a front-row seat to the future of medicine. Here’s what had doctors buzzing:
Buzz in the chat this week is exactly what Longevity Docs is about: highly intellectual conversations, real-world clinical questions, and debates where no one is afraid to say “I don’t know” out loud. We covered too many topics to pick just one, so here’s the map of what we discussed - and the key takeaways from each, with opposing viewpoints that keep this community sharp.
1. Psychedelics & Longevity
Ketamine, psilocybin, and ayahuasca sparked a big conversation: are these just tools for trauma and mental health, or do they have true longevity effects through neuroplasticity, telomerase, and cellular pathways? The consensus: big promise, early data, and a massive need for standards, ethics, and clinical frameworks.
“If neuroplasticity is a longevity pathway, psychedelics belong in the conversation.”
“Until we have long-term data, psychedelics are intriguing but not core longevity tools.”
2. Mitochondrial Testing & Organic Acids
Docs compared tools like Mitoswab, GDF-15, organic acids, acylcarnitines, and oxidative stress panels. The thread exposed a shared reality: many markers are noisy, but in the right combination, they become clinically powerful. The big ask: clearer algorithms, not just longer lab panels.
“Mito testing is essential: we’re treating energy systems, not lab values in isolation.”
“If only 10–20% of markers change management, we need to stop over-ordering.”
3. Peptides, Compounding Pharmacies & Supplement Hype
From peptide sourcing to pre-op peptide regimens and GLP-1 timing, the group traded best practices and red flags. Fatty15 became the case study of the week: a perfect example of how elegant biochemical narratives can outpace actual clinical necessity.
“Peptides are powerful levers when used precisely and ethically.”
“Most of this is brilliant marketing on top of basic biochemistry. We must protect patients from hype.”
4. Stem Cells, MSCs & Knee OA
Knee osteoarthritis prompted a rich discussion: autologous adipose/BMAC/PRP vs. allogeneic MSCs in places like the Bahamas, plus emerging procedures like Arthrosamid and Autocart. The community sits at the edge of innovation and regulation daily — and that tension was obvious.
“Allogeneic MSCs at scale are the future; dose matters, and we finally have it.”
“Autologous approaches remain my first choice until allogeneic data and regulation catch up.”
5. Devices, Metrics & Environment (Scales + Water)
Black Friday turned into a masterclass on RENPHO, Styku, InBody, Hume, and home body comp tools. Then the conversation moved to water: EWG reports, Cloud RO, Springwell, Aquatru, PristineHydro. The theme: measure more, yes — but measure what actually drives behavior and outcomes.
“Affordable devices that patients actually use beat perfect devices that collect dust.”
“If the data isn’t accurate or actionable, more gadgets just create more noise.”
Underneath all of this was something quieter but powerful: the Thanksgiving thread. Gratitude for a group where curiosity outruns dogma, where aging feels like a variable, not a verdict, and where you can ask about anything from telomerase to tap water and get an honest answer.
That’s the real buzz in the chat this week.
Not just the topics. The tribe.
Not a member yet? Join the debate in the WhatsApp group
Longevity Docs is a highly vetted, invitation-only community for physicians shaping the future of longevity medicine. Apply to connect with our team.
Each week, I highlight studies that could shape the future of longevity medicine. This week is very cardio focused
GDF15: a meaningful biomarker for mitochondrial dysfunction
In patients with late-onset MADD, GDF-15 levels were significantly elevated—likely reflecting mitochondrial dysfunction activating the integrated stress response.
This positions GDF-15 as a useful biomarker for tracking symptom severity and disease progression. Orphanet Rare Dis.
For longevitydocs: GDF-15 is a biomarker worth following.
Ambient AI: reducing exhaustion in clinicians
A pragmatic randomized trial in NEJM AI showed that ambient AI systems reduced work exhaustion and interpersonal disengagement among healthcare practitioners.
Notably, these tools did not increase professional fulfillment—but they did meaningfully reduce burnout-related strain.
For longevitydocs: AI can lighten clinician workload, but it can’t replace purpose. Use it to protect energy, not define culture.
Every week, I track funding, FDA approvals, product launches, and breakthrough announcements shaping longevity medicine.
PHARMA
GLP-1s disappoint in Alzheimer’s trials
Science reports that oral semaglutide failed to slow cognitive decline in two large, 2-year Alzheimer’s trials (~3,800 patients), despite improving some disease biomarkers. Hopes that GLP-1s could treat established neurodegeneration took a major hit, even though they still look promising for prevention and cardio-metabolic risk.
For longevitydocs: GLP-1s remain powerful tools for obesity, diabetes, and cardiovascular risk not a magic bullet for Alzheimer’s once disease is underway.
AI/TECH
An AI System With Detailed Diagnostic Reasoning Makes Its Case
Harvard researchers have developed an AI system called Dr. CaBot that spells out its reasoning as it works through challenging medical cases and reaches a diagnosis. For the first time, the New England Journal of Medicine has published an AI-generated diagnosis (produced by Dr. CaBot) alongside one from a human clinician in its medical case study series.
For longevitydocs: The tool will accelerate how we learn, teach, and interpret complex cases but the last mile of judgment, protocols, and patient decisions will remain critical
POLICIES
U.S. launches Apollo-style “Genesis Mission” to accelerate AI-driven scientific discovery
Scientific American calls it the largest mobilization of federal scientific resources since Apollo. The Genesis Mission will unite AI with massive federal datasets (NASA, NIH, DOE) to automate experiment design, accelerate simulations, and compress discovery timelines from years to days. The ambition: breakthrough advances in fusion, quantum systems, materials science, and medicine.
For Longevity Docs: AI will accelerate drug discovery, biomarker development, and aging research. But translation into clinical practice still requires physician judgment.
CARE DELIVERY
AI is becoming the “first stop” for frustrated patients
According to the New York Times , millions of Americans are using AI to compensate for a medical system that feels rushed, impersonal, and inaccessible.
Chatbots offer instant responses and emotional validation, but also provide false reassurance, incorrect advice, and scripts to challenge physicians.
For longevitydocs: If we don’t lead the integration of AI into clinical care, the gap between information and safe interpretation will widen. Longevity medicine must set the standard for AI-enabled, physician-led care.
AI & TECH MASTERMIND | JANUARY 31, NYC
We’re bringing together 150 longevity physicians building AI-powered longevity practices.
If you’re still figuring out which AI tools are HIPAA-compliant, how to integrate wearables into clinical decisions, or whether proteomics is ready for practice, this is where you get answers from physicians already doing it.
What we’re covering:
Next-gen biomarkers (proteomics, epigenetics, multi-omics)
Wearables and continuous monitoring: clinical-grade vs. wellness theater
NeuroTech and brain aging protocols
Performance metrics that track biological age
AI imaging that catches what radiologists miss
Tech stacks that actually work (EMR integration, dashboards, APIs)
Clinical workflow tools: triage, documentation, protocol generation
AI-powered practice growth without physician burnout
The debate: frontier tech vs. what’s ready now
Your Monday morning action plan: 90-day implementation roadmap
Small group. Curated. Limited to 150 Physicians only.
VIP (50 spots) - Includes private dinner with speakers
In-Person (limited) - Full access to all sessions and networking
Virtual - Live-stream and replay for those who can’t travel
Early-bird ends December 15.
Applications reviewed on a rolling basis. We’re looking for physicians serious about building AI-enabled longevity practices.
Where to Find Us
San Francisco · Dec 5 - Longevitydocs Table
Novato · Dec 6-8 – Longevity Clinic Roundtable
Las Vegas · Dec 12-13 – A4M Conference
Las Vegas · Jan 6-9, 2026 – CES
New York · January 31 – Longevitydocs AI/Tech Mastermind
Cannes, France · June 9-11, 2026 – Longevitydocs Summit
The world’s largest physician network in longevity medicine
longevitydocs.™ is the world’s largest physician network in longevity medicine, serving 600+ vetted physicians across 50+ countries. We unite physicians, industry, and institutions to build the trusted global infrastructure that makes longevity medicine the new standard of care.
Our Pioneering Approach: Uniting Science, Clinical Practice, and Culture
Professional Network
Global Longevity Community: A curated community of leading longevity physicians fostering peer learning, clinical collaboration, and professional growth
Medical Education
Certified longevitydocs.™ (CLD): The first structured, physician-led clinical curriculum for longevity medicine - comprehensive, evidence-based, and practice-ready.
Clinical Research
Longevity Research Network: Clinical research infrastructure enabling rapid generation of real-world evidence across the Longevity Docs network.
Cultural Experiences
Global Events: From Cannes to New York, our Summits, Awards, Masterminds, and Jefferson Dinners convene top researchers, clinicians, investors, and government officials to shape longevity medicine’s growth, investment, and policy.
Intelligence
Strategic Insights: Weekly syntheses of scientific breakthroughs, clinical best practices, business signals, and global market analysis for Fortune 500 companies - the industry’s trusted source of intelligence.
Not a member yet? Longevity Docs is an invitation-only network of 600+ physicians shaping the future of longevity medicine through clinical collaboration, certification, and global events.
Subscribe to the Longevity Docs Newsletter
Stay connected with a global network of 500+ physicians in 50+ countries advancing longevity medicine. Get evidence-based insights, clinical updates, and exclusive access to the community shaping the future of longevity care.
Newsletter Disclaimer:
This is a genuinely meaningful move for the field! I see the same bottleneck you’re naming: we’re drowning in biomarkers, wearables, and “AI insights”, but the scarce resource is still clinical interpretation + accountable protocols, turning measurement into outcomes without drifting into wellness theater.
What I particularly appreciate about longevitydocs.network is the emphasis on the “physician layer” as infrastructure (trial leadership, protocol development, claims validation, education), not just a directory. If longevity medicine is going to mature into a credible discipline, it needs exactly this: vetted clinicians, standardized endpoints (function, frailty metrics, cardiometabolic risk, cognition), and guardrails around hype (peptides, supplements, noisy panels) so patients aren’t paying for certainty theater.
Excited to see physician-led networks that can partner with industry while keeping the north star clear: rigor, safety, and measurable healthspan!